Although Chang HY et al. reported a higher prescription rate, SGLT-2 inhibitor was only the fourth most commonly prescribed antihyperglycemic agent after metformin, Dpp-4 inhibitor, and sulphonylurea in their cohort of heart failure patients (18). Here, DPP4 is linked to heart failure.